Review

Dermatographism with vulvar symptoms

Sydney Rivera MPH a,*, Ginat W. Mirowski DMD, MD, FAAD b, c

a School of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
b Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana
c Department of Oral Pathology, Medicine and Radiology, Indiana University School of Dentistry, Indianapolis, Indiana

A B S T R A C T

Dermatographism (DG) is characterized by a localized, inducible, wheal-and-flare response along the distribution of mechanical pressure. We report an illustrative case of DG with vulvar symptoms (DG-VS) and review the literature on this rarely recognized but easily treated etiology of vulvar complaints. A 35-year-old woman presented with a 1-year history of vulvar pruritus unresponsive to antifungal, antibacterial, and steroid treatments. A prior punch biopsy was nondiagnostic. Vulvar examination revealed normal architecture and no cutaneous abnormalities. She was markedly dermatographic with a scratch test. DG-VS was diagnosed. The patient achieved complete symptomatic control on low-dose hydroxyzine. She maintains excellent control at 3.5 years. In the literature, a typical patient with DG-VS is of reproductive age, with several years’ history of vulvar symptoms (itching, burning, pain, or swelling) and repeated empiric treatment for infectious/inflammatory etiologies. Exacerbation with sexual activity, menstruation, or wearing tight clothing is characteristic and supports the role of mechanical pressure in inducing focal symptoms. Dermatologic changes to the vulvar skin are rarely noted. DG-VS is diagnosed based on clinical findings, symptom patterns, and a positive scratch test and is treated with antihistamines. DG-VS remains absent from current vulvar disease guidelines. In the complex world of vulvar pain and itch, an etiology so easily screened for and readily treated warrants consideration.

© 2021 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
biopsy demonstrated mild telangiectasias and attenuation of collagen (possibly representing steroid atrophy) without evidence of inflammation or atypia. Periodic acid–Schiff stain testing was negative.

Upon presentation to author G.W.M., the patient reported waxing and waning itch that distracted her from daily tasks, kept her up at night, and was “absolutely horrendous” about 2 days out of every 2 weeks. The patient was not sexually active. Vulvar exposures included laundry detergent, unscented bar soap, and lotion limited to the mons. On visual inspection, follicular papules were noted on the mons. Vulvar architecture was normal without atrophy, erythema, lichenification, or other dermatologic changes. The patient demonstrated a marked wheal-and-flare response on the back with a scratch test (Fig. 1).

The patient was diagnosed with folliculitis on the mons and DG-VS. She was advised to discontinue local personal care products and was prescribed oral hydroxyzine 10 to 20 mg nightly, with an additional 10 to 20 mg every 6 hours as needed. At 1-month follow-up, the patient reported complete symptomatic relief. At 3.5 years, she is no longer dermatographic on scratch test and experiences recurrence only when holding hydroxyzine.

Discussion

DG has a prevalence of 2% to 5% in the general population (Kirby et al., 1971; Wong et al., 1984). Pressure-induced wheals are characteristically a cutaneous phenomenon. Mucosal involvement is recognized but has not been rigorously studied (Binnadi and Almazrooa, 2016; Golberg et al., 2014; Lambiris and Greaves, 1997; O’Hare and Sherertz, 2000; Perniciaro et al., 1993; Sherertz and Thiers, 1994; Wong et al., 1984). The prevalence of DG with genital symptoms is unknown. Patients with DG may not recognize or report these symptoms, and clinicians are unlikely to ask about them (Lambiris and Greaves, 1997).

There are few publications regarding DG-VS. The literature is limited to letters and brief reports. Table 1 summarizes the three English-language case reports of DG-VS (Lambiris and Greaves, 1997; Perniciaro et al., 1993; Sherertz and Thiers, 1994). Two series are summarized in Table 2 (Golberg et al., 2014; O’Hare and Sherertz, 2000). An abstract described three more cases (Goldman, 2000), and there are two French-language reports (Lübke et al., 2000; Mathelier-Fusade et al., 2007).

The typical patient is of reproductive age with several years’ history of vulvar symptoms and has undergone empiric antimicrobial, antifungal, and topical steroid treatment. Although infectious workup is often warranted, repeated workup may delay appropriate care, increase morbidity, create undue financial burden, and be a significant source of distress and frustration.

DG-VS presents with itching, burning, pain, or swelling. Exacerbation with sexual activity, menstruation, or wearing tight clothing is characteristic and supports the role of mechanical pressure in generating focal symptoms. Some level of vulvar swelling with sexual arousal is physiologic and normal, but pain or pruritus indicate a pathologic process, such as infection, allergy (Golberg et al., 2014; Mathelier-Fusade et al., 2007), inflammatory dermatoses, pudendal neuropathy (Ghizzani et al., 2019), or DG-VS.

DG presents with wheal formation at sites of mechanical pressure (e.g., purse straps, clothing). However, patients with DG-VS may not be aware of or may not associate typical DG symptoms with genital complaints. Although our patient was dermatographic, neither she nor her five prior clinicians had associated DG with her vulvar pruritus.

Dermatologic changes to the vulvar skin are rarely appreciated. Erythema is nonspecific. Edema may be observed or induced with manipulation (Sherertz and Thiers, 1994). Vaginal discharge and architectural changes are not associated. Lack of lichenification speaks against a strong itch–scratch cycle component, although nighttime rubbing may induce or exacerbate pruritus or burning.

As of 2016, the consensus-approved screening test for DG is scratch testing: stroking the skin of the back with a firm, non-pointed object in a linear pattern and observing for wheal formation within 2 to 10 minutes (Magerl et al., 2016). In the context of vulvar complaints, patients should be screened for a history of urticaria or DG and assessed via scratch testing (Lambiris and Greaves, 1997; Mathelier-Fusade et al., 2007). This quick and simple point-of-care procedure provides a great opportunity to explain the suspected clinical picture to the patient. Scratch testing of the vulva is not warranted. A positive scratch test and characteristic vulvar symptoms that resolve with treatment of DG is confirmatory of DG-VS (Goldman, 2000; Mathelier-Fusade et al., 2007; O’Hare and Sherertz, 2000).

As of 2018, the guidelines on chronic inducible urticaria recommend a second-generation H1 antihistamine as first-line treatment for symptomatic DG (Magerl et al., 2016; Zuberbier et al., 2018). First-generation H1 antihistamines may be used when nighttime itch is distressing (Patel and Yasipovitch, 2010). Hydroxyzine, a first-generation H1 antihistamine, has demonstrated efficacy in several studies of DG (Kulthanan et al., 2020). In DG-VS, first- or second-generation antihistamines have been used as monotherapy (Lübke et al., 2000; Mathelier-Fusade et al., 2007; Sherertz and Thiers, 1994). Lübke et al. (2000) noted that 11 of 14 patients experienced symptomatic relief, and five relapsed with treatment cessation. Reported adjuvants include tricyclic antidepressants (doxepin, amitriptyline), topical agents (adrenaline, halcinone), and lubricant for intercourse (Goldman, 2000; Lambiris and Greaves, 1997; Mathelier-Fusade et al., 2007; O’Hare and Sherertz, 2000; Perniciaro et al., 1993). Overall, antihistamine treatment with or without adjuvants leads to excellent symptom resolution.

Based on our clinical experience and review of the literature, we recommend hydroxyzine 10 to 40 mg nightly with 10 to 20 mg every 6 hours as needed. A known side effect of hydroxyzine is drowsiness, making this therapy particularly helpful for patients who experience sleep disturbance due to itching, as in the case of our patient. In our experience, nighttime dosing has been extremely well tolerated. First-generation antihistamines are not recommended for long-term use in older patients.

For this patient, cessation of personal care product use and initiation of hydroxyzine led to symptomatic relief. She found that symptom control was contingent on continuing hydroxyzine. Encouraging cessation of genital personal care products is standard of care in patients with genital complaints, but this measure alone does not lead to symptomatic resolution in patients with DG-VS.
Table 1
Case reports of DG with vulvar symptoms

| Authors            | Patient | Clinical history                                                                 | Previous treatment                                                                 | Physical examination                                                                 | Additional workup                                                                 | Treatments                                                                 |
|--------------------|---------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Perniciaro et al., 1993 | 38-year-old woman | 3 years of constant burning and irritation of introitus with dyspareunia and dysmenorrhea; pruritus absent | • Topical antifungal                                                             | • No apparent vulvar abnormality                                                       | • KOH negative                                                               | Terfenadine 60 mg 2 × per day + cyproheptadine 4 mg 3 × per day |
| Sherertz and Thiars, 1994 | 28-year-old woman | Intermittent vulvar pruritus and burning of unspecified duration exacerbated by exercise, intercourse, and menses | • Topical antifungal                                                             | • No apparent vulvar abnormality                                                       | • Not described                                                               | Astemizole 10 mg every night at bedtime for 3 months with no recurrence at 1 year |
| Lambris and Greaves, 1997 | 25-year-old woman | 8 years of chronic generalized urticaria, with “several years” of persistent burning, swelling, and pruritus of the introitus, exacerbated by menses and intercourse | • Systemic antifungal, Topical antifungal, Also treated sexual partner | • No apparent vulvar abnormality                                                       | • Vaginal smear, Candida culture, and acetowhitenng negative       | Cetirizine 10 mg orally every day, with 2% topical adrenaline cream as needed |

DG, dermatographism

Table 2
Case series of DG with vulvar symptoms

| Authors             | Design         | Participants                                                                 | Patient characteristics                                                                 | Suggested workup                                                                 | Suggested management                                           |
|---------------------|----------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------|
| O’Hare and Sherertz, 2000 | Observational study | 16 patients (26.7%) with vulvodynia at one genital dermatology clinic found to have DG | • Mean age: 43.9 years (range, 18–78 years)                                            | • Scratch test                                                                  | • Antihistamines, Tricyclic antidepressants (doxepin, amitriptyline) |
| Golberg et al., 2014 | Case series    | 6 patients presenting for suspected latex allergy with vulvovaginal symptoms presumably associated with condom use, found to have DG | • Mean age: 25.3 years (range, 22–37 years)                                            | • Scratch test, Latex allergy testing                                         | • None described                                             |

DG, dermatographism

* Characteristics of entire study group; not specific to the 16 patients with DG.

Conclusions and future directions

DG-VS is an identifiable and treatable cause of vulvar symptoms. Still, the literature on vulvar health scarcely includes DG-VS in the differential diagnosis (Byth, 1998; Gopal et al., 2016; Sand and Thomsen, 2018). Notably, DG-VS is not included in dermatologic, gynecologic, and sexual health guidelines or reviews of vulvar pain (Bornstein et al., 2019, 2016; Committee on Practice Bulletins - Gynecology, 2020; Lynch et al., 2012; Mauskar et al., 2020). Lack of inclusion creates a challenge for dermatologists, gynecologists, and others who care for patients with vulvar complaints and inevitably delays treatment, diagnosis, and research.

In seeking a diagnosis, our patient faced numerous failed treatments, unnecessary and repeated diagnostic tests, and persistent, worsening itch. In the complex world of vulvar pain and itch, an etiology so easily screened for and treated warrants consideration. Inclusion of DG in practice guidelines, continuing medical education, and care recommendations from key vulvar disease resources is a vital step to educate health care providers and stimulate further research.

Declaration of Competing Interest

None.

Funding

None.
Study approval

The author(s) confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies.

References

Binnnadi N, Almazrooa S. Dermographism in the oral cavity. Am J Case Rep 2016;17:421–4.

Bornstein J, Goldstein AT, Stockdale CK, Bergeron S, Pukall C, Zolinoun D, et al. 2015 ISSVD, ISSWHS, and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. J Sex Med 2016;13:607–12.

Bornstein J, Preti M, Simon JA, As-Sanie S, Stockdale CK, Stein A, et al. Descriptors of vulvodynia: A multisocietal definition consensus (International Society for the Study of Vulvovaginal Disease, the International Society for the Study of Women Sexual Health, and the International Pelvic Pain Society). J Low Genit Tract Dis 2019;23:161–3.

Byth JL. Understanding vulvodynia. Australas J Dermatol 1998;39:139–50.

Committee on Practice Bulletins - Gynecology. Diagnosis and management of vulvar skin disorders: ACOG practice bulletin, number 224. Obstet Gynecol 2020;136:e1–14.

Ghizzani A, Carta S, Casoni A, Ferrata P, Luisi S, Fortina M. Differentiating overlapping symptoms of vulvodynia and pudendal neuralgia. Br J Pain 2019;13:54–8.

Goldberg O, Johnston GA, Wilkinson M. Symptomatic dermatographism mimicking latex allergy. Dermatitis 2014;25:101–3.

Goldman LE. Dermatographic urticaria: Consider dermatographism in vulvovaginal itch. OB/GYN News 2000.

Gopal G, Hadoua E, vulvae Mahmood TPruritus. Obstet Gynaecol Reprod Med 2016;26:95–100.

Kirby JD, Matthews CNA, James J, Duncan EHL, Warin RF. The incidence and other aspects of factitious wealng (dermographism). Br J Dermatol 1971;85:331–5.

Kulthanan K, Ungprasert P, Tuchinda P, Chularojanamonti L, Rajitharanawong C, Kiratiwongwan R, et al. Symptomatic dermatographism: A systematic review of treatment options. J Allergy Clin Immunol Pract 2020;8:3141–61.

Lambiris A, Greaves M. Dyspareunia and vulvodynia: Unrecognised manifestations of symptomatic dermographism. Lancet 1997;349:28.

Lübbe J, Valitron A, Pedrazetti P, Arechalde A, Harms M. Vulvodynia and factitious urticaria. Ann Dermatol Venereol 2000;127:377–9.

Lynch PJ, Moyal-Barraco M, Scurry J, Stockdale C. 2011 ISSVD terminology and classification of vulvar dermatological disorders: An approach to clinical diagnosis. J Low Genit Tract Dis 2012;16:339–44.

Magerl M, Altrichter S, Bortzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias – The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and version. Allergy 2016;71:780–802.

Mathelier-Fusade P, Amsler E, Leynadier F. Dermographism: An unknown etiology of vulvodynia. Ann Dermatol Venereol 2007;134:275–6.

Maurer M, Fluhrl JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract 2018;6:1119–30.

Mauskar MM, Marathe K, Venkatesan A, Schlosser BJ, Edwards L. Vulvar diseases: Conditions in adults and children. J Am Acad Dermatol 2020;82:1287–98.

Nobles T, Muse ME, Schmieder GJ. Dermatographism. Treasure Island, FL: StatPearls Publishing; 2020.

O’Hare PM, Sherertz EF. Vulvodynia: A dermatologist’s perspective with emphasis on an irritant contact dermatitis component. J Women’s Health Gend Based Med 2000;9:565–9.

Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010;11:1663–82.

Perniciaro C, Bustamante AS, Gutierrez MM. Two cases of vulvodynia with unusual causes, Acta Derm Venereol 1993;73:227–8.

Sand FL, Thomsen SF. Skin diseases of the vulva: Eczematous diseases and contact urticaria. J Obstet Gynaecol 2018;38:20–5.

Sherertz EF, Thurs BH. Clinical pearl: Symptomatic dermatographism as a cause of genital pruritus. J Am Acad Dermatol 1994;31:1040–1.

Wong RC, Fairley JA, Ellis CN. Dermographism: A review. J Am Acad Dermatol 1978;11:642–52.

Zuberbier T, Aberer W, Asero R, Latif AHA, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393–414.